In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

A recursive vibe journalism experiment in which Microsoft 365 Copilot's 'Prompt Coach' agent is used to wholly create an ...

Many in the AI community believe that the next major revolution will be the era of self-improving AI where AI can improve ...

Spaceship hosting offers low prices and decent performance, though it has a few quirks.

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

DeFi has evolved from 2020’s yield chaos into real financial infrastructure. Here’s how stablecoins, RWAs, and institutions ...

Demis Hassabis says the level of investment in some parts of the tech industry had become detached from commercial realities ...